Moderna, Inc. (MRNA) saw its shares plunge 5.16% in Friday's trading session, as the vaccine industry grapples with significant regulatory challenges and policy shifts. The steep decline comes amid growing concerns over the Trump administration's dramatic reworking of U.S. public-health agencies' approach to vaccines, which is creating an unpredictable environment for vaccine manufacturers.

The vaccine sector has been under pressure since President Trump announced his intention to appoint Robert F. Kennedy Jr. as the head of the Department of Health and Human Services. Kennedy has been leading a sweeping campaign against the vaccine status quo, including funding cuts to messenger RNA-based vaccine research - a technology that forms the cornerstone of Moderna's product portfolio. Additionally, the CDC's vaccine advisory committee, now stacked with critics of mRNA-based vaccines, is expected to issue narrow recommendations that could severely limit insurance coverage for Covid-19 shots.

These developments have sapped investor enthusiasm for vaccine stocks, with Moderna being particularly vulnerable due to its focus on mRNA technology. The company's shares have already declined more than 40% since Trump's announcement last November, and today's sharp drop suggests that market participants are increasingly wary of the challenges facing vaccine manufacturers in this new regulatory landscape. As the industry faces an uncertain future, investors appear to be reassessing the growth prospects and potential risks associated with companies heavily invested in vaccine development and production.